placeholder image
L. I. Wagner All authors
About
Publications While At 开云体育
selected publications
Journal Article
  • Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: patient-reported outcomes in ECOG-ACRIN EA1131. 
    Cancer. 2024
  • Financial hardship among patients with early-stage colorectal cancer. 
    JAMA network open. 2024
  • Patient-reported financial burden of treatment for colon or rectal cancer. 
    JAMA network open. 2024
  • Randomized study of induction with bendamustine-rituximab 卤 bortezomib and maintenance with rituximab 卤 lenalidomide for MCL. 
    Blood. 2024
  • Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131. 
    Journal of Clinical Oncology. 2021
  • Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial. 
    Cancer medicine. 2020
  • Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. 
    Journal of Clinical Oncology. 2020
  • Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 Study. 
    Journal of Clinical Oncology. 2019
  • E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN Cancer Research Group. 
    Journal of Clinical Oncology. 2017
    • Contact
    full name
  • L. I. Wagner
    • Quick Info
    Publications
    Publications in the past 10 years based solely on publications while at 开云体育. Publications in prior years appear in grey.
    Collaboration